Wyeth Premarin low-dose
Wyeth's low-dose Premarin (.45 mg estrogens) approved by FDA April 25. Estrogen level is 28% lower than standard .625 mg. FDA action comes one month after approval of low-dose Prempro (.45 mg estrogens/1.5 mg medroxyprogesterone) ("The Pink Sheet" March 17, p. 4). Both hormone therapies will launch this summer...
You may also be interested in...
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.